StageZero Life Sciences Ltd
- LAST PRICE0.0400
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots0.0250/ 2
- Open / Previous Close--- / 0.0400
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
StageZero Life Sciences Ltd | 4.9M | 0.0x | --- |
RAMM Pharma Corp | 1.2M | -0.1x | --- |
COSCIENS Biopharma Inc | 15.0M | -0.4x | --- |
Innovotech Inc | 7.2M | -18.7x | --- |
Principal Technologies Inc | 5.9M | -2.1x | --- |
Appili Therapeutics Inc | 4.2M | -1.2x | --- |
Company Information
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.
Contact Information
- Headquarters
- 30-70 East Beaver Creek RoadRICHMOND HILL, ON, Canada L4B 3B2
- Phone
- 905-209-2030
- Fax
- 905-209-2030
Executives
- Chairman of the Board, Chief Executive Officer
- James Howard-Tripp
- Chief Financial Officer, Chief Operating Officer
- Matthew Pietras
- Independent Director
- Harry Glorikian
- Independent Director
- Garth Macrae
- Independent Director
- Rory Riggs
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.9M |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | 123.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.16 |
EPS | --- |
Book Value | $-0.10 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
